Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisResearch in context

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisResearch in context

Summary: Background: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, sotorasib concentrations, and the incidence of hepa...

Full description

Bibliographic Details
Main Authors: Sophie M. Ernst, Maaike M. Hofman, Tessa E. van der Horst, Marthe S. Paats, Frank W.J. Heijboer, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Robin Cornelissen, Jan H. von der Thüsen, Peter de Bruijn, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Stijn L.W. Koolen, Anne-Marie C. Dingemans
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:EBioMedicine
Subjects:
NSCLC
KRAS
Sotorasib
Hepatitis
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424001099

Internet

http://www.sciencedirect.com/science/article/pii/S2352396424001099

Similar Items